Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Guided Therapeutics, Inc. (OTC: GTHP).

Full DD Report for GTHP

You must become a subscriber to view this report.


Recent News from (OTC: GTHP)

Guided Therapeutics Provides Progress Update on International Activities
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, continues to make progress with commercial activities internationally. 1. China. We are in the process of transferring manufacturing to our commercial...
Source: Business Wire
Date: June, 21 2018 10:19
New Data Released at European Conference Demonstrates LuViva® Advanced Cervical Scan Detects Cervical Cancer Earlier than Pap and HPV tests
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Russian and Eastern European distribution partner, Newmars Group Kft., along with Hungarian physicians, reported new clinical res...
Source: Business Wire
Date: May, 22 2018 08:05
Dr. Gene Cartwright, CEO of Guided Therapeutics Joins Everett Jolly on Uptick Newswire's "Stock Day" Podcast to Discuss LuViva® Advanced Cervical Scan
PHOENIX, May 16, 2018 (GLOBE NEWSWIRE) -- Guided Therapeutics, Inc. (OTCQB:GTHP) (the “Company”) announced CEO Dr. Gene Cartwright’s interview on Uptick Newswire’s "Stock Day” podcast with Everett Jolly. Guided Therapeutics has developed a cervical cance...
Source: GlobeNewswire
Date: May, 16 2018 08:00
Guided Therapeutics Completes License Agreement with Turkish Distribution Partner with Ministry of Health Backing
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has signed a definitive, multiyear license agreement with its Turkish distribution partner ITEM for the manufacture of patented si...
Source: Business Wire
Date: April, 02 2018 10:02
Guided Therapeutics gets regulatory approval for sale in India
Guided Therapeutics ( OTCQB:GTHP +52.4% ) has received regulatory approval from the Indian Ministry of Health & Family Welfare to allow commercialization of the LuViva device and disposables. The Ministry concluded that the LuViva device is “Non Invasive” More news on...
Source: SeekingAlpha
Date: March, 12 2018 13:31
Guided Therapeutics Achieves Regulatory Approval for Sale in India
Plans for commercialization in world’s second most populous country underway Guided Therapeutics, Inc. (OTCQB: GTHP) reported today that the Company received Regulatory Approval from the Indian Ministry of Health & Family Welfare to allow commercialization of the LuViva dev...
Source: Business Wire
Date: March, 12 2018 11:24
Guided Therapeutics Ships 8 LuViva Devices and 4,500 Single Use Cervical Guides to Indonesia in Q4 2017
Highest Volume of Business in a Quarter for the World’s Fourth Largest Population Guided Therapeutics, Inc. (OTCQB: GTHP) reported today record sales for a quarter in Indonesia, with eight LuViva® Advanced Cervical Scans shipped in the fourth quarter of last year. In addit...
Source: Business Wire
Date: March, 01 2018 11:33
Independent Research on Trending Growth Companies: Guided Therapeutics and ImageWare
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Guided Therapeutics, Inc. (OTCQB: GTHP) and ImageWare Systems, Inc. (OTCQB: IWSY), including recent technical analysis and consolidated fundamental informat...
Source: ACCESSWIRE IA
Date: March, 01 2018 08:30
Guided Therapeutics Signs Preliminary License Agreement with Turkish Distribution Partner Based on Ministry of Health Support for the LuViva Advanced Cervical Scan
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has signed a preliminary license agreement with its Turkish distribution partner ITEM for the manufacture of patented single-patie...
Source: Business Wire
Date: December, 08 2017 08:45
Guided Therapeutics Continues to Grow International Sales with New Order of Disposables from Indonesia and Letter of Intent for Distribution in India
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has received a new order of 4,000 single-patient-use Cervical Guides from its Indonesia distributor and that it has signed a Letter...
Source: Business Wire
Date: November, 28 2017 10:13

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.00040.00040.00040.000360,977,041
2018-12-120.00030.000390.00050.000364,532,217
2018-12-110.00030.00040.00040.000322,251,309
2018-12-100.00040.00040.00040.0003159,225,319
2018-12-070.00050.00050.00050.0003120,228,599

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-137,548,70960,977,04112.3796Cover
2018-12-1244,144,97164,532,21768.4076Short
2018-12-1110,734,47122,251,30948.2420Short
2018-12-1048,662,598159,125,31930.5813Cover
2018-12-0764,322,852120,228,59953.5005Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GTHP.


About Guided Therapeutics, Inc. (OTC: GTHP)

Logo for Guided Therapeutics, Inc. (OTC: GTHP)

Guided Therapeutics, Inc. is the developer of the LuViva Advanced Cervical Scan, a rapid and painless test for the early detection of disease that leads to cervical cancer. LuViva is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. LuViva works by shining light on the cervical and reading the returned light with a spectrometer. LuViva looks for chemical and physical markers of precancer. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. For more information, visit www.guidedinc.com.

 

Contact Information

 

 

Current Management

  • Gene S. Cartwright / CEO, CFO
    • Gene Cartwright joined us in January as the President, Chief Executive Officer and Acting Chief Financial Officer. He was elected as a director on January , . His most recent position was with Omnyx, LLC, a Joint Venture between GE Healthcare and the University of Pittsburgh Medical Center, where, as CEO for over four years he founded and managed the successful development of products for the field of Digital Pathology. Prior to his work with Omnyx, LLC, he was President of Molecular Diagnostics for GE Healthcare. Prior to GE, Dr. Cartwright was Divisional Vice President/General Manager for Abbott Diagnostics Molecular Diagnostics business. In his year career at Abbott, he also served as Divisional Vice President for U.S. Marketing for five years. He received a Masters of Management degree from Northwestern s Kellogg School of Management and also holds a Ph.D. in chemistry from Stanford University and an AB from Dartmouth College. Dr. Cartwright brings over years of experience working in the IVD diagnostics industry. He has great experience in the diagnostics market both in the development and introduction of new diagnostics technologies, as well as extensive successful commercial experience with global businesses.
  • Mark L. Faupel / COO
    • Dr. Faupel currently serves as a managing member of Shenghuo Medical, LLC Shenghuo , a company with licensing rights in several Asian countries for the Company s LuViva Advanced Cervical Scan. He previously served on the Company s board of directors through and has more than years of experience in developing noninvasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Dr. Faupel was cofounder of the Company and also served as the Company s Chief Executive Officer from May through . Prior thereto was the Company s Chief Technical Officer from April to May . Dr. Faupel has served as a National Institutes of Health reviewer, is the inventor on U.S. patents and has authored numerous scientific publications and presentations, appearing in such peerreviewed journals as The Lancet. Dr. Faupel earned his Ph.D. in neuroanatomy and physiology from the University of Georgia.
  • James Clavijo / CFO
  • Bill Wells / Director, Corp. Comm.
  • Michael C. James / Chairman
    • Michael C. James has served as a member of our Board of Directors since March and as Chairman of the Board since October , . Mr. James is also the Managing Partner of Kuekenhof Capital Management, LLC, a private investment management company, Chief Executive Officer and the Chief Financial Officer of Inergetics, Inc., a nutraceutical supplements company and also the Chief Financial Officer of Terra Tech Corporation, which is a hydroponic and agricultural company. He also holds the position of Managing Director of Kuekenhof Equity Fund, L.P. and Kuekenhof Partners, L.P. Mr. James currently sits on the Board of Directors of Inergetics Inc. Mr. James was Chief Executive Officer of Nestor, Inc. from January to September and served on their Board of Directors from July to June . He was employed by Moore Capital Management, Inc., a private investment management company from to and held position of Partner. He was employed by Buffalo Partners, L.P., a private investment management company from to and held the position of Chief Financial and Administrative Officer. He began his career in as a staff accountant with Eisner LLP. Mr. James received a B.S. degree in Accounting from Farleigh Dickinson University in .
  • Richard P. Blumberg /
    • Mr. Blumberg has been a longtime investor in the Company. Since , Mr. Blumberg has been a Principal at Webster, Mrak amp Blumberg, a medicallegal and class action labor litigation firm. He is also currently the Managing Member of Shenghuo Medical, LLC Shenghuo , a company with licensing rights in several Asian countries for the Company s LuViva Advanced Cervical Scan, and is the Managing Member of Elysian Medical, LLC, a company with worldwide rights for certain breast cancer detection technology. He served from to as Chief Executive Officer of Energy Logics, a wind power company that developed projects in Alberta, Canada and Montana. Mr. Blumberg holds a B.S. in Electrical Engineering and Computer Science from the University of Illinois and received a J. D. from Stanford University. He also brings extensive experience as a venture capitalist specializing in hightech and life science companies.
  • Gene S. Cartwright /
    • Gene Cartwright joined us in January as the President, Chief Executive Officer and Acting Chief Financial Officer. He was elected as a director on January , . His most recent position was with Omnyx, LLC, a Joint Venture between GE Healthcare and the University of Pittsburgh Medical Center, where, as CEO for over four years he founded and managed the successful development of products for the field of Digital Pathology. Prior to his work with Omnyx, LLC, he was President of Molecular Diagnostics for GE Healthcare. Prior to GE, Dr. Cartwright was Divisional Vice President/General Manager for Abbott Diagnostics Molecular Diagnostics business. In his year career at Abbott, he also served as Divisional Vice President for U.S. Marketing for five years. He received a Masters of Management degree from Northwestern s Kellogg School of Management and also holds a Ph.D. in chemistry from Stanford University and an AB from Dartmouth College. Dr. Cartwright brings over years of experience working in the IVD diagnostics industry. He has great experience in the diagnostics market both in the development and introduction of new diagnostics technologies, as well as extensive successful commercial experience with global businesses.
  • John E. Immhoff /
    • Dr. Imhoff has served as a member of our Board of Directors since April . Dr. Imhoff is an ophthalmic surgeon who specializes in cataract and refractive surgery. He presently serves as a member of the Hawaiian Eye Foundation s Scientific Advisory Board. He is also one of our principal shareholders and invests in many other private and public companies. He has a B.S. in Industrial Engineering from Oklahoma State University, an M.D. from the University of Oklahoma and completed his ophthalmic residency at the Dean A. McGee Eye Institute. He has worked as an ophthalmic surgeon and owner of Southeast Eye Center since . He serves on the compensation and audit committees.

Current Share Structure

  • Market Cap: $122,557 - 03/09/2018
  • Authorized: 1,000,000,000 - 04/13/2017
  • Issue and Outstanding: 19,453,469 - 11/07/2017

 


Recent Filings from (OTC: GTHP)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2017
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: November, 13 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 25 2017
Withdrawal of registration statement filed under the Securities Act
Filing Type: RWFiling Source: edgar
Filing Date: September, 25 2017

 

 


Daily Technical Chart for (OTC: GTHP)

Daily Technical Chart for (OTC: GTHP)


Stay tuned for daily updates and more on (OTC: GTHP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GTHP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GTHP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GTHP and does not buy, sell, or trade any shares of GTHP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/